Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of rintatolimod to enhance the immune mediated effects of CPIs in patients with advanced solid tumors

Next Previous
Search
Trial Profile

Phase I/II study of rintatolimod to enhance the immune mediated effects of CPIs in patients with advanced solid tumors

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Jun 2018 New trial record
    • 31 May 2018 According to a Hemispherx Biopharma media release, This study will be led by Pawel Kalinski, MD, PhD, who currently serves as the Vice Chair for Translational Research and Professor of Oncology in the Department of Medicine and as the Co-Leader for the Tumor Immunology & Immunotherapy Program at Roswell Park.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top